Accuracy of Two Continuous Glucose Monitoring Devices During Aerobic and High-Intensity Interval Training in Individuals with Type 1 Diabetes.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Cuerda Del Pino A
- Martín-San Agustín R
- Laguna Sanz AJ
- Diez JL
- Palanca A
- Gumbau-Gimenez M
- Ampudia-Blasco FJ
- Bondia J
Grupos
Abstract
BBACKGROUND: This study aimed to evaluate the accuracy of Dexcom G6 (DG6) and FreeStyle Libre-2 (FSL2) during aerobic training and HIIT in individuals with type 1 diabetes (T1D). METHODS: Twenty-six males (mean age 29.3 ± 6.3 years and mean duration of diabetes 14.9 ± 6.1 years) participated in this study. Interstitial glucose levels were measured using DG6 and FSL2, while plasma glucose levels were measured every 10 min using YSI 2500 as the reference for glucose measurements in this study. The measurements began 20 min before the start of exercise and continued for 20 min after exercise. Seven measurements were taken for each subject and exercise. RESULTS: Both DG6 and FSL2 devices showed significant differences compared to YSI glucose data for both aerobic and HIIT exercises. Continuous glucose monitoring (CGM) devices exhibited superior performance during HIIT than aerobic training, with DG6 showing a mean absolute relative difference (MARD) of 14.03% versus 31.98%, respectively. In the comparison between the two devices, FSL2 demonstrated significantly higher effectiveness in aerobic training, yet its performance was inferior to DG6 during HIIT. According to the 40/40 criteria, both sensors performed similarly, with marks over 93% for all ranges and both exercises, and above 99% for HIIT and in the >180 mg/dL range, which is in accordance with FDA guidelines. CONCLUSIONS: The findings suggest that the accuracy of DG6 and FSL2 deteriorates during and immediately after exercise, but remains acceptable for both devices during HIIT. However, accuracy is compromised with DG6 during aerobic exercise. This study is the first to compare the accuracy of two CGMs, DG6 and FSL2, during two exercise modalities, using plasma glucose YSI measurements as the gold standard for comparisons.
Datos de la publicación
- ISSN/ISSNe:
- 1520-9156, 1557-8593
- Tipo:
- Article
- Páginas:
- 411-419
- PubMed:
- 38215205
- Factor de Impacto:
- 2,660 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
DIABETES TECHNOLOGY & THERAPEUTICS MARY ANN LIEBERT, INC
Citas Recibidas en Web of Science: 2
Documentos
- No hay documentos
Filiaciones
Keywords
- Type 1 diabetes; Accuracy; Continuous glucose monitoring; High-intensity interval training; Aerobic exercise
Proyectos y Estudios Clínicos
SELECT - EFECTOS DE SEMAGLUTIDA EN LOS RESULTADOS CARDIOVASCULARES EN PERSONAS CON SOBREPESO U OBESIDAD.
Investigador Principal: JUAN FRANCISCO MERINO TORRES
EX9536-4388 . 2019
LONG-TERM EFFECTS OF SEMAGLUTIDE ON DIABETIC RETINOPATHY IN SUBJECTS WITH TYPE 2 DIABETES (FOCUS).
Investigador Principal: JUAN FRANCISCO MERINO TORRES
NN9535-4352 . 2019
ESTUDIO MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA EVALUAR EL IMPACTO DE EVOLOCUMAB SOBRE LOS ACONTECIMIENTOS CARDIOVASCULARES MAYORES EN PACIENTES CON RIESGO CARDIOVASCULAR ELEVADO SIN INFARTO DE MIOCARDIO O ICTUS PREVIO
Investigador Principal: JUAN FRANCISCO MERINO TORRES
20170625 . 2019
COMPARACIÓN DEL EFECTO DE TIRZEPATIDA FRENTE AL DE DULAGLUTIDA SOBRE LOS ACONTECIMIENTOS CARDIOVASCULARES MAYORES EN PACIENTES CON DIABETES DE TIPO 2 (SURPASS-CVOT).
Investigador Principal: JUAN FRANCISCO MERINO TORRES
I8F-MC-GPGN . 2020
Estudio de fase 3, aleatorizado, doble ciego, para investigar la eficacia y seguridad de LY3502970 administrado una vez al día por vía oralen comparación con placebo en participantes adultos con obesidad o sobrepeso con comorbilidades relacionadas con e/ peso (ATTAIN-1)",
Investigador Principal: JUAN FRANCISCO MERINO TORRES
J2A-MC-GZGP . 2023
REIMAGINE-2: Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4/2.4 mg and 1.0/1.0 mg once weekly versus semaglutide 2.4 mg and 1.0 mg, cagrilintide 2.4 mg and placebo in participants with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor.
Investigador Principal: JUAN FRANCISCO MERINO TORRES
NN9388-4896 . 2023
Cita
Cuerda Del Pino A,Martín R,Laguna AJ,Diez JL,Palanca A,ROSSETTI P,Gumbau M,Ampudia FJ,Bondia J. Accuracy of Two Continuous Glucose Monitoring Devices During Aerobic and High-Intensity Interval Training in Individuals with Type 1 Diabetes. Diabetes Technol Ther. 2024. 26. (6):p. 411-419. IF:5,700. (1).